Cargando…
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therapies. We previously demonstrated the ability of PXT864, a comb...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693228/ https://www.ncbi.nlm.nih.gov/pubmed/32815196 http://dx.doi.org/10.1002/jnr.24714 |